Oral capsule
KPV
A three-amino-acid fragment studied for its anti-inflammatory profile.
KPV is a three-amino-acid fragment of alpha-MSH studied for anti-inflammatory activity, including in the gut. It has not been through the clinical trials the FDA requires to approve a drug. rhome's KPV is compounded as an oral capsule by a licensed pharmacy from your clinician's prescription.
From $119 per month1not FDA approved
Compounded under a temporary federal policy (HHS, October 28, 2026) while the FDA decides whether to add it to its compounding list. That is not FDA approval, and the policy can change.
Your rhythm
On the schedule your clinician sets.
What to expect
Living with KPV.
- 01
An oral capsule, no injection
- 02
Compounded by licensed U.S. pharmacies
- 03
Clinician review before every renewal
- 04
Message your care team any time
Questions
Straight answers.
No. On October 28, 2026, the U.S. Department of Health and Human Services issued an interim enforcement-discretion policy: it does not intend to act against licensed pharmacies that compound this substance from a patient-specific prescription, under set conditions, while the FDA finishes its rulemaking. That is not FDA approval. The substance has not been evaluated by the FDA for safety, effectiveness, or quality the way an approved drug is, and it has not been added to the FDA's 503A bulk drug list; an FDA advisory committee recommended adding it in July 2026 and the FDA has not decided. The policy is temporary and can change.
Not at rhome. The federal interim policy covers KPV in oral and topical forms only, so rhome offers the capsule.
Then a box at the door.
Your first box, in your treatment’s colour, with a card on top with your name on it.